Arax Advisory Partners’s Avadel Pharmaceuticals AVDL Stock Holding History

Arax Advisory Partners’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8	Closed	-$172	–	3818
2025 Q4	$172	Sell	8 -271	-97%	-$5.26K	﹤0.01%	3745
2025 Q3	$4.26K	Buy	+279	New	+$3.63K	﹤0.01%	2916

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Arax Advisory Partners's AVDL Position: Q1 2026 in Review

Arax Advisory Partners sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 8 shares — an estimated $172 sold.

Arax Advisory Partners first reported a position in AVDL in Q3 2025 and held it in 2 quarters. The position peaked at $4.26K in Q3 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Arax Advisory Partners reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Arax Advisory Partners sold 8 Avadel Pharmaceuticals shares in Q1 2026, an estimated $172.
Arax Advisory Partners first reported a position in Avadel Pharmaceuticals in Q3 2025 and held it in 2 quarters.
Arax Advisory Partners's Avadel Pharmaceuticals position peaked at $4.26K in Q3 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.